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T cell homeostasis must be tightly controlled. In this issue of Immunity, Cho et al. (2010) describe results that
begin to define the roles of the T cell receptor, self-peptide-MHC ligands, cytokines, and membrane rafts in
this dynamic process.In the past few years, there have
been increasing efforts to understand all
aspects of how a T cell receptor (TCR)
influences many different biological activ-
ities of T cells. The TCR has long been
known to control the primary function
of T cells, that being recognition and
elimination of antigen, but it is now clear
that TCRs are also involved in the daily
maintenance of T cells in the periphery.
The structural side of immunology has
focused attention on how a single TCR
can cross-react with many different
peptide-MHC (pMHC) ligands (Yin and
Mariuzza, 2009). On the cellular side,
efforts have concentrated on describing
the specific self-pMHC ligands that
are recognized by a particular T cell
(Wucherpfennig and Gagnon, 2009) and
understanding the necessity for these
interactions during the life of a T cell in
the periphery.
TCR:self-pMHC interactions are re-
quired for a T cell to survive in the
periphery and to undergo homeostatic
proliferation, as occurs in the lympho-
penic state. In this issue of Immunity,
Cho et al. (2010) put us one step closer
to understanding the key mechanisms
involved in the cellular process of T cell
homeostasis. Cho et al. begin by showing
that naive peripheral CD8+ T cells, but
not CD4+ T cells, can proliferate when
exposed to IL-2 or IL-15, even in the
apparent absence of an agonist for the
TCR. This result may seem contradictory
to what we have learned, that T cells
require signals through the TCR and other
molecules such as CD28 for mature T cell
activation. However, the study proceeds
to show that these CD8+ T cells actually
are receiving signals via their TCRs,
through interactions with self-pMHC.
This conclusion was reached by studying
naive T cells derived from normal C57
mice and various TCR transgenic mice,together with antigen-presenting cells
with deficiencies in MHC-I or the peptide
transporter Tap1. In each case, IL-2
responsiveness was greatly reduced in
the absence of MHC-I.
What are the qualities of TCR interac-
tions with self-pMHC that provide signals
through certain TCRs, but not others? In
this report by Cho et al. and elsewhere,
a hierarchy of TCRs has been described
based on the propensity of transgenic
T cells carrying those receptors to prolif-
erate in response to lymphopenia (e.g.,
OT-1 > 2C > HY; OT-1 > P14 > HY). These
TCRs are specific for different agonist
pMHC: OT-1 for OVA/Kb, 2C for SIY/Kb
and p2Ca/Ld, P14 for viral peptide
gp33/Db, and HY for the endogenous
male antigen HY/Db. This propensity for
homeostatic proliferation has been attrib-
uted to a putative distribution of affinities
for self-pMHC, from high to low for the
OT-1, P14/2C, and HY TCR transgenic
systems, respectively. This observed
hierarchy is based entirely on biological
read-outs, where T cells are exposed to
antigen-presenting cells that express an
array of endogenous pMHC. There are
no binding measurements for these inter-
actions, and in fact, only a couple of self-
peptides have been incriminated as puta-
tive ligands (e.g., Cappa192–99 for OT-1
and dEV8 for 2C [Santori et al., 2002]).
Because there are no data about the
actual TCR:self-pMHC affinities involved,
or indeed even about how many self-
pMHC could serve as ligands for a given
TCR, the processes that arise from TCR:
self pMHC interactions cannot distinguish
several possible scenarios, each of which
could explain the hierarchies that are
associated with activities of the different
TCRs. Thus, increased TCR reactivity
with self-pMHC could be due to (1) higher
affinity for a single self pMHC ligand, (2)
a higher density of a single self-pMHCImmunity 32,ligand, (3) greater cross-reactivity with
a large number of different self pMHC-
ligands, or (4) a combination of these
binding properties. The various trans-
genic TCRs could even bind to self
peptides restricted by MHC alleles other
than the allele associated with agonist.
In the absence of any data to distinguish
these possibilities, we refer to the interac-
tions of a TCR with pMHC as ‘‘reactiv-
ities’’ rather than ‘‘affinities’’ (Figure 1). It
is also worth pointing out that even good
agonists can have very weak binding
affinities (KD values as high as 300 mM
have been described in a number of
studies), and thus, it is likely that the affin-
ities involved in self-pMHC reactions will
actually be below those that can be
measured by current techniques.
Regardless of the mechanism of self-
pMHC binding by the different transgenic
TCRs, T cells with higher reactivity for
self-pMHC were more sensitive to IL-2
and IL-15 than T cells with lower reactivity
for self-pMHC. Cho et al. examined
several key features that point to a
plausible mechanism. GM1, a marker for
lipid enriched rafts, was upregulated on
the most self-reactive T cells and was
directly correlated with sensitivity to IL-2.
The important role of lipid rafts was sup-
ported by experiments in which the
compound methyl-b-cyclodextrin, which
disrupts rafts, inhibited IL-2 responsive-
ness. Furthermore, the IL-2 receptor
b (IL-2Rb) was found to colocalize with
high-density patches of GM1. These find-
ings suggested that the pathway that
leads from binding of self-pMHC by
TCRs to IL-2 responsiveness involves
the enhanced generation of rafts that
contain IL-2Rb (Figure 1). As described
by Cho et al., physiologically, this process
might result in enhanced sensitivity to
IL-15 or IL-7 (perhaps in combination
with IL-12, which was also shown toFebruary 26, 2010 ª2010 Elsevier Inc. 145
Figure 1. TCR Reactivity with Self-Peptide-MHC Directs T Cell Responsiveness during
Peripheral Homeostasis
T cells express clonotypic TCRs with varying degrees of reactivity with endogenous peptide-MHC. The
membranes of CD8+ T cells with different reactivities are depicted. T cells with lower self-reactivity
have low amounts of GM1 (a sphingolipid associated with lipid rafts) and low amounts of CD5, considered
an inhibitor of signaling. These cells do not proliferate in response to added gc cytokines, such as IL-2 or
IL-15. T cells with intermediate self-reactivity have slightly higher amounts of both GM1 and CD5, and they
respond with some proliferation when exposed to gc cytokines. T cells with higher self-reactivity have
upregulated GM1 expression within lipid rafts (symbolized by red shading of the membrane) that colocal-
izes with IL-2Rb, although overall IL-2Rb expression is unchanged. Although CD5 is also upregulated, it
does not colocalize with GM1. These cells proliferate well when provided with IL-2 or IL-15 in the absence
of additional TCR agonist signals.
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eration).
Enhanced responsiveness to IL-2 in
naive CD8+ T cells was also associated
with higher expression of CD5, a negative
regulator of TCR signaling (Tarakhovsky
et al., 1995) that appears to reduce activa-
tion responses via recruitment of the
phosphatase SHP-1. Increased expres-
sion of CD5 on more self-reactive T cells
might make sense, as this would pro-
vide amechanism for dampening a poten-
tial autoreactive pathology. However, the
association of cytokine responsiveness
with CD5 expression was not strictly
correlative, as CD4+ T cells (which were
nonresponsive to cytokines) had high
expression of CD5. Hence, CD5 may
indeed be controlling some activity of
T cells with the most self-reactive TCRs,
but it does not appear to be directly, or
solely, responsible for enhanced IL-2
sensitivity.
The role of coreceptor in this process
is undoubtedly important for the T cell146 Immunity 32, February 26, 2010 ª2010 Eresponse to self pMHC, perhaps pro-
viding the key feature that distinguishes
the cytokine responsiveness of CD8+
T cells from the nonresponsiveness of
CD4+ T cells. It is quite likely that CD8 is
required for both synergistic binding of
these low-affinity self-pMHC-I ligands
and for signaling that ultimately leads to
cytokine responsiveness. By contrast,
CD4 is thought to contribute less energy
to class II pMHC binding, which may in
part account for reduced reactivity with
self pMHC. Furthermore, because the
MHC II ligand for CD4+ T cells is only
expressed on professional antigen-pre-
senting cells, whereas the ligand for
CD8+ T cells (MHC I) is expressed on all
nucleated cells, it stands to reason that
the frequency of TCR:self-pMHC II inter-
actions in the periphery is far lower than
TCR:self-pMHC I; these continual interac-
tions may allow CD8+ T cells, rather than
CD4+ T cells, to maintain increased sensi-
tivity to cytokine. Although the behavior of
CD4+ T cells in responses to self-pMHClsevier Inc.has been studied more extensively (e.g.,
Wong et al., 2001; Wucherpfennig and
Gagnon, 2009), the contribution of self
pMHC to recognition by CD8+ T cells
has gained some ground (e.g., Yachi
et al., 2005; also see Krogsgaard et al.,
2007 for review of CD4 and CD8 cells).
The study by Cho et al. provides yet
additional evidence that not all peripheral
CD8+ T cells are equal. Support has
continued to mount to show that T cells
can use various mechanisms to ‘‘tune’’
the sensitivities of TCR-mediated sig-
naling (Dustin, 2009). These mechanisms
include modified expression levels of
important molecules, such as the TCR
complex or CD8, altered glycosylation
states of surface molecules, or localiza-
tion of molecules to organized lipid micro-
clusters or domains (as seen in Cho et al.
for the IL-2Rb and elsewhere for CD4 and
CD8). Most studies have illustrated these
principles using stimulation by agonist
ligands. It will be interesting to now see
how TCR binding to self-pMHC influences
these and other properties. Additional
issues that remain to be addressed
include details regarding the specific self
pMHC ligands for a particular T cell, the
role of CD5 in light of its higher levels on
the most IL-2-sensitive CD8 cells, and
further information about the molecular
links between TCR, CD3, CD8 signaling,
and cytokine responsiveness.
Finally, it should also be pointed out
that these findings have some relevance
to adoptive T cell therapies (Schmitt
et al., 2009). For example, efforts to trans-
fer T cells that are transduced with a TCR
that is specific for tumor-associated
antigen will need to consider whether
the TCR will be capable of mediating
homeostatic processes in the recipient.
Assuming that these findings extend
to the human system, this work reveals
possible strategies to test the transduced
T cells for in vitro surrogate markers that
predict their capacity to undergo homeo-
static proliferation.
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CD95 has long been viewed as a death receptor regulating apoptosis. In this issue of Immunity, Letellier et al.
(2010) tell us a different story, about the capability of CD95L to regulate leukocyte recruitment to sites of
inflammation.It is well established that the signaling pair
CD95L-CD95, also known as FASL-FAS,
signals to apoptosis in a variety of cellular
contexts. This paradigm has been re-
cently challenged by data showing that
CD95 may fulfill a range of physiological
nonapoptotic functions, including a role
as a proinflammatory mediator. In this
issue of Immunity, Letellier et al. (2010)
provide compelling evidence of the capa-
bility of CD95 to trigger signaling events
leading to leukocyte integrin-dependent
adhesion and migration and expand our
perception of the role of CD95 in nona-
poptotic functions.
CD95 is a prototypical member of the
tumor necrosis factor receptor super-
family containing an intracellular death
domain in its cytoplasmic tail, which trans-
mits a death signal to the cell (Strasser
et al., 2009). CD95 exists as a homotrimer
and is activated through binding to trimers
of its ligand CD95L (Siegel et al., 2000). In
the extrinsic (or death-receptor-regulated)
pathway, engagement of the death
receptor CD95 by CD95 ligand (CD95L)
leads to the activation of caspase 8 by
the adaptor protein FADD (FAS-associ-
ated death domain) and the formation of
the death-inducing signaling complex
(DISC) through homologous domain inter-
actions (Bouillet and O’Reilly, 2009).
Active caspase 8 then cleaves and acti-
vates caspase 3, caspase 6, and caspase7, which targets vital cellular substrates,
thus inducing cell death (Bouillet and
O’Reilly, 2009). The expression of CD95L
has to be carefully regulated to prevent
unintentional killing of healthy cells
because CD95 is widely expressed and
ligation of CD95 by CD95L potently trig-
gers apoptosis in many cell types (Bouillet
and O’Reilly, 2009).
It is largely accepted that several
members of the TNF-R family, including
some that are classified as death recep-
tors, and their corresponding ligands
exert non-apoptotic functions, such as
the induction of cellular activation, prolif-
eration, differentiation, or migration. By
applying an articulated experimental ap-
proach involving both animal models
and human subjects, Letellier et al. (2010)
investigated the involvement of CD95L as
a proinflammatory determinant in spinal
cord injury (SCI). The authors showed
that injury to the central nervous system
(CNS) increases CD95L surface expres-
sion on peripheral blood cells in rodents
and humans, thus establishing a potential
source for CD95L leading to CNS dam-
age. Specifically, neutrophils and macro-
phageswere found to be themajor source
of CD95L leading to CNS damage. Impor-
tantly, neutralization experiments and
gene expression analysis showed that
CNS damage is dependent on CD95L-
mediated proinflammatory activity andnot to direct CD95-induced apoptosis
of resident neural spinal cells, bringing
strong evidence for the role of CD95 in
nonapoptotic events. In particular, the
authors suggested that myeloid cells infil-
trate the lesion site in a CD95L-dependent
manner and produce proinflammatory
cytokines upon interaction with other im-
mune cells or with CNS-resident cells,
leading to the amplification of the immune
response. The authors further character-
ized the activity of CD95L-CD95 on leuko-
cyte function and find a role in regulation
of integrin-dependent adhesion and mi-
gration. CD95L also regulated cell recruit-
ment in a model of peritonitis, suggesting
that its involvement in leukocyte traf-
ficking is not restricted to the CNS. Inter-
estingly, the study by Letellier et al. (2010)
suggests that the interaction between
leukocyte-expressed CD95 and CD95L,
leading to enhanced migration and sub-
sequent tissue destruction, occurs in the
periphery before the migration of myeloid
cells in the target tissue. It is tempting to
speculate that pharmacological modula-
tion of CD95L-CD95 interaction may rep-
resent a potential therapeutic approach in
some inflammatory diseases.
The study by Letellier et al. (2010)
expands our view of death receptors and
definitively brings CDC95L-CD95 to the
realm of cell trafficking and inflammation.
This study also raises a number ofFebruary 26, 2010 ª2010 Elsevier Inc. 147
